Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in shares of Drugs Made In America Acquisition II Corp. (NASDAQ:DMII – Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 2,000,000 shares of the company’s stock, valued at approximately $19,960,000.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Magnetar Financial LLC purchased a new position in Drugs Made In America Acquisition II in the 4th quarter worth approximately $26,730,000. Glazer Capital LLC purchased a new stake in Drugs Made In America Acquisition II during the 4th quarter valued at $23,264,000. First Trust Capital Management L.P. purchased a new stake in Drugs Made In America Acquisition II during the 4th quarter valued at $20,474,000. Hudson Bay Capital Management LP bought a new stake in shares of Drugs Made In America Acquisition II in the 4th quarter worth $19,493,000. Finally, Millennium Management LLC purchased a new position in shares of Drugs Made In America Acquisition II in the fourth quarter worth $14,850,000.
Wall Street Analysts Forecast Growth
A number of research analysts have recently issued reports on DMII shares. Weiss Ratings raised Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (e+)” rating in a report on Thursday, June 11th. Wall Street Zen upgraded Drugs Made In America Acquisition II from a “sell” rating to a “hold” rating in a report on Sunday, May 10th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has an average rating of “Sell”.
Drugs Made In America Acquisition II Stock Performance
Shares of Drugs Made In America Acquisition II stock opened at $10.10 on Tuesday. Drugs Made In America Acquisition II Corp. has a twelve month low of $9.86 and a twelve month high of $10.11. The firm’s 50 day moving average is $10.08.
Drugs Made In America Acquisition II Profile
Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.
The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.
Featured Articles
- Five stocks we like better than Drugs Made In America Acquisition II
- AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next
- Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now
- Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?
- Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight
Want to see what other hedge funds are holding DMII? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Drugs Made In America Acquisition II Corp. (NASDAQ:DMII – Free Report).
Receive News & Ratings for Drugs Made In America Acquisition II Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Drugs Made In America Acquisition II and related companies with MarketBeat.com's FREE daily email newsletter.
